Tofogliflozin

1. Tofogliflozin decreases eGFR decline in humans (between-group difference: 6.14 mL/min/1.73 m2).

   Humanspatients with type 2 diabetes mellitus72 monthsn = 598

   Long-term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study · Journal of diabetes investigation · 19 Sep 2026

1. Tofogliflozin decreases succinate in humans.

   Human trialtype 2 diabetes and biopsy-confirmed MASLD48 weeks

   Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study · Biochemistry and biophysics reports · 14 Sep 2026

Succinate →

1. Tofogliflozin increases acetyl-CoA in humans.

   Human trialtype 2 diabetes and biopsy-confirmed MASLDliver48 weeks

   Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study · Biochemistry and biophysics reports · 14 Sep 2026

acetyl-CoA →